Myth-buster
A meta-analysis of 773 patients found NAC linked to a 34% lower risk of post-ERCP pancreatitis — but the result wasn't statistically significant, and it didn't reduce severity either.
This is among the first indexed studies on NAC for this specific clinical setting, so the evidence is too weak to support routine use; the null result and lack of effect on severity mean the popular notion that NAC prevents pancreatitis isn't backed by this analysis.
Post-ERCP pancreatitis is a common complication of a procedure to open bile ducts. NAC, an antioxidant, was tested in several trials pooled here. While the risk ratio of 0.66 hints at a possible benefit, the confidence interval crossed 1 (0.38 to 1.16), meaning the result could be due to chance. Crucially, when pancreatitis did occur, NAC didn't make it less severe — so any potential effect is narrow and uncertain.
Where this fits in the evidence
This is among the first studies we've indexed on N-Acetyl Cysteine for Reduced Incidence of Post-ERCP Pancreatitis — treat it as an early signal until more research accumulates.
The study
- Meta-Analysis
- n = 773
- 2025-11-04
- BMC gastroenterology
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.